299 related articles for article (PubMed ID: 12081594)
1. Immune responsiveness in renal transplant recipients: mycophenolic acid severely depresses humoral immunity in vivo.
Rentenaar RJ; van Diepen FN; Meijer RT; Surachno S; Wilmink JM; Schellekens PT; Pals ST; van Lier RA; ten Berge IJ
Kidney Int; 2002 Jul; 62(1):319-28. PubMed ID: 12081594
[TBL] [Abstract][Full Text] [Related]
2. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses.
Struijk GH; Minnee RC; Koch SD; Zwinderman AH; van Donselaar-van der Pant KA; Idu MM; ten Berge IJ; Bemelman FJ
Kidney Int; 2010 Nov; 78(9):934-40. PubMed ID: 20703211
[TBL] [Abstract][Full Text] [Related]
3. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
Hazzan M; Labalette M; Copin MC; Glowacki F; Provôt F; Pruv FR; Noël C
J Am Soc Nephrol; 2005 Aug; 16(8):2509-16. PubMed ID: 15987748
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo lymphocyte proliferative function is severely inhibited in renal transplant patients on mycophenolate mofetil treatment.
Hutchinson P; Jose M; Atkins RC; Holdsworth SR
Transpl Immunol; 2004; 13(1):55-61. PubMed ID: 15203129
[TBL] [Abstract][Full Text] [Related]
5. Impact of maintenance immunosuppressive regimens--balance between graft protective suppression of immune functions and a near physiological immune response.
Weimer R; Deisz S; Dietrich H; Renner F; Bödeker RH; Daniel V; Kamali-Ernst S; Ernst W; Padberg W; Opelz G
Transpl Int; 2011 Jun; 24(6):596-609. PubMed ID: 21401729
[TBL] [Abstract][Full Text] [Related]
6. Humoral immunity after kidney transplantation: impact of two randomized immunosuppressive protocols.
Legris T; Picard C; Moal V; Burtey S; Loundou A; Purgus R; Dussol B; Berland Y; Vacher-Coponat H
Ann Transplant; 2013 Nov; 18():622-34. PubMed ID: 24231646
[TBL] [Abstract][Full Text] [Related]
7. Outcome in cadaveric renal transplant recipients treated with cyclosporine A and mycophenolate mofetil versus cyclosporine A and azathioprine.
Lee CM; Markezich AJ; Scandling JD; Dafoe DC; Alfrey EJ
J Surg Res; 1998 May; 76(2):131-6. PubMed ID: 9698512
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic approach to immunosuppressive therapies using calcineurin inhibitors and mycophenolate mofetil.
Millán O; Brunet M; Campistol JM; Faura A; Rojo I; Vidal E; Jiménez O; Vives J; Oppenheimer F; Martorell J
Clin Chem; 2003 Nov; 49(11):1891-9. PubMed ID: 14578321
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
10. Everolimus-treated renal transplant recipients have a more robust CMV-specific CD8+ T-cell response compared with cyclosporine- or mycophenolate-treated patients.
Havenith SH; Yong SL; van Donselaar-van der Pant KA; van Lier RA; ten Berge IJ; Bemelman FJ
Transplantation; 2013 Jan; 95(1):184-91. PubMed ID: 23222818
[TBL] [Abstract][Full Text] [Related]
11. The effect of sirolimus- or cyclosporine-based immunosuppression effects on T-cell subsets in vivo.
Libetta C; Sepe V; Zucchi M; Portalupi V; Meloni F; Rampino T; Dal Canton A
Kidney Int; 2007 Jul; 72(1):114-20. PubMed ID: 17410097
[TBL] [Abstract][Full Text] [Related]
12. Early steroid withdrawal protocol with basiliximab, cyclosporine and mycophenolate mofetil in renal-transplant recipients.
Kato Y; Tojimbara T; Iwadoh K; Koyama I; Nanmoku K; Kai K; Sannomiya A; Nakajima I; Fuchinoue S; Teraoka S
Int Immunopharmacol; 2006 Dec; 6(13-14):1984-92. PubMed ID: 17161352
[TBL] [Abstract][Full Text] [Related]
13. Graft survival following living-donor renal transplantation: a comparison of tacrolimus and cyclosporine microemulsion with mycophenolate mofetil and steroids.
Bunnapradist S; Daswani A; Takemoto SK
Transplantation; 2003 Jul; 76(1):10-5. PubMed ID: 12865780
[TBL] [Abstract][Full Text] [Related]
14. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
Abou-Ayache R; Büchler M; Lepogamp P; Westeel PF; Le Meur Y; Etienne I; Lobbedez T; Toupance O; Caillard S; Goujon JM; Bergougnoux L; Touchard G
Nephrol Dial Transplant; 2008 Jun; 23(6):2024-32. PubMed ID: 18199693
[TBL] [Abstract][Full Text] [Related]
15. Conversion from cyclosporine A to mycophenolate mofetil protects recipient kidney and prevents intimal hyperplasia in rat aortic allografts.
Shimizu H; Takahashi M; Takeda S; Inoue S; Fujishiro J; Hakamata Y; Kaneko T; Murakami T; Takeyoshi I; Morishita Y; Kobayashi E
Transpl Immunol; 2004 Nov; 13(3):219-27. PubMed ID: 15381205
[TBL] [Abstract][Full Text] [Related]
16. Erythrocyte sodium lithium countertransport in renal transplant recipients with mycophenolate mofetil and low-dose cyclosporine.
Vareesangthip K; Hanlakorn P; Suwannaton L; Larpkitkachorn R; Chuawattana D; Pidetcha P; Ong-Aj-Yooth L
Transplant Proc; 2004 Dec; 36(10):3032-5. PubMed ID: 15686688
[TBL] [Abstract][Full Text] [Related]
17. Low-dose versus high-dose cyclosporine induction protocols in renal transplantation.
Ghafari A; Makhdoomi K; Ahmadpour P; Afshari AT; Fallah MM; Rad PS
Transplant Proc; 2007 May; 39(4):1219-22. PubMed ID: 17524937
[TBL] [Abstract][Full Text] [Related]
18. In vitro effects of mycophenolic acid on the nucleotide pool and on the expression of adhesion molecules of human umbilical vein endothelial cells.
Raab M; Daxecker H; Karimi A; Markovic S; Cichna M; Markl P; Müller MM
Clin Chim Acta; 2001 Aug; 310(1):89-98. PubMed ID: 11485760
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
Asberg A; Midtvedt K; Line PD; Narverud J; Holdaas H; Jenssen T; Reisaeter AV; Johnsen LF; Fauchald P; Hartmann A
Transplantation; 2006 Jul; 82(1):62-8. PubMed ID: 16861943
[TBL] [Abstract][Full Text] [Related]
20. T-cell reactivity during tapering of immunosuppression to low-dose monotherapy prednisolone in HLA-identical living-related renal transplant recipients.
Gerrits JH; van de Wetering J; Weimar W; van Besouw NM
Transplantation; 2009 Mar; 87(6):907-14. PubMed ID: 19300195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
